title: Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
abstract: Alemtuzumab is an antibody binding to CD52, an antigen expressed on lymphocytes. This immunotherapy has been tested as potential therapy in haematological malignancies. We report adenoviral and enteroviral infections and an EBV positive B-cell lymphoma after alemtuzumab therapy. These fatal opportunistic complications have been rarely, if ever, reported before.
authors.affiliation: Department of Infectious Diseases, University Hospital, Grenoble, France. NRoch@chu-grenoble.fr
authors.forename: Nathalie
authors.initials: N
authors.lastname: Roch
authors.forename: Dimitri
authors.initials: D
authors.lastname: Salameire
authors.forename: Remy
authors.initials: R
authors.lastname: Gressin
authors.forename: Patrice
authors.initials: P
authors.lastname: Morand
authors.forename: Olivier
authors.initials: O
authors.lastname: Epaulard
authors.forename: Patricia
authors.initials: P
authors.lastname: Pavese
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Brion
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Stahl
mesh_terms: D000258:Adenovirus Infections, Human / Q000821:virology; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004769:Enterovirus Infections / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000821:virology; D017809:Fatal Outcome; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D016393:Lymphoma, B-Cell / Q000821:virology*; D008297:Male; D009894:Opportunistic Infections / Q000821:virology*; D012751:Sezary Syndrome / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab